Page 1

17 February 2021 MARKET RELEASE NZX / ASX Code : EBO EBOS 2021 Half - Year Results EBOS GROUP LIMITED EBOS REPORTS ANOTHER RECORD RESULT AND DOUBLE - DIGIT NPAT GROWTH Key highlights of the first half included : • Revenue of $ 4.7 billion ( up 6.3 % ) ; • • • • • . • • Statutory Net Profit after Tax ( NPAT ) of $ 92.9 million ( up 13.7 % ) ; Underlying Net Profit after Tax ( Underlying NPAT ) of $ 94.3 million ( up 14.2 % ) ; Interim dividend declared of NZ 42.5 cents per share ( up 13.3 % ) ; Very strong performances from both our Healthcare and Animal Care segments , with Healthcare's Underlying EBIT up 11.2 % and Animal Care's EBIT up 25.6 % ; Excellent operating cash flow of $ 98.7 million ( up 33.0 % ) ; Acquisition of CH2's vet distribution business for approximately $ 9 million , which further strengthens Lyppard's market position in this sector . This adds to the previously announced acquisition of Cryomed , which further expands our medical devices business ; and Further strengthening of our balance sheet , with Net Debt : EBITDA reducing to 1.00x ( 1.11x at June 2020 ) . Following further refinancing initiatives in August 2020 and February 2021 , EBOS has no debt maturities until 2H FY23 . A $ 1 Total Revenue EBITDA EBIT Net Profit after Tax Earnings per Share Operating cash flow ROCE Net Debt : EBITDA³ Interim Dividend Statutory Results Underlying Results $ 4,653.3m up 6.3 % $ 4,653.3m up 6.3 % $ 182.2m up 9.0 % $ 184.1m up 9.3 % $ 147.8m up 11.5 % $ 145.9m up 11.1 % $ 92.9m up 13.7 % 56.9 cents up 12.3 % $ 98.7m up 33.0 % n / a n / a NZ 42.5cps up 13.3 % $ 94.3m up 14.2 % 57.8 cents up 12.7 % n / a 17.5 % up 0.4 % ² 1.00x down 0.11x² n / a 1 All amounts included are denoted in Australian dollars unless otherwise stated . 2 Compared to June 2020 . 3 3 Calculated in accordance with banking covenants .